Platelets and cardiac arrhythmia
- PMID: 21423401
- PMCID: PMC3059929
- DOI: 10.3389/fphys.2010.00166
Platelets and cardiac arrhythmia
Abstract
Sudden cardiac death (SCD) remains one of the most prevalent modes of death in industrialized countries, and myocardial ischemia due to thrombotic coronary occlusion is its primary cause. The role of platelets in the occurrence of SCD extends beyond coronary flow impairment by clot formation. Here we review the substances released by platelets during clot formation and their arrhythmic properties. Platelet products are released from three types of platelet granules: dense core granules, alpha-granules, and platelet lysosomes. The physiologic properties of dense granule products are of special interest as a potential source of arrhythmic substances. They are released readily upon activation and contain high concentrations of serotonin, histamine, purines, pyrimidines, and ions such as calcium and magnesium. Potential arrhythmic mechanisms of these substances, e.g., serotonin and high energy phosphates, include induction of coronary constriction, calcium overloading, and induction of delayed after-depolarizations. Alpha-granules produce thromboxanes and other arachidonic-acid products with many potential arrhythmic effects mediated by interference with cardiac sodium, calcium, and potassium channels. Alpha-granules also contain hundreds of proteins that could potentially serve as ligands to receptors on cardiomyocytes. Lysosomal products probably do not have an important arrhythmic effect. Platelet products and ischemia can induce coronary permeability, thereby enhancing interaction with surrounding cardiomyocytes. Antiplatelet therapy is known to improve survival after myocardial infarction. Although an important part of this effect results from prevention of coronary clot formation, there is evidence to suggest that antiplatelet therapy also induces anti-arrhythmic effects during ischemia by preventing the release of platelet activation products.
Keywords: arrhythmias; cardiac; platelets; sudden death; ventricular fibrillation.
Figures


Similar articles
-
Abnormalities in sodium current and calcium homoeostasis as drivers of arrhythmogenesis in hypertrophic cardiomyopathy.Cardiovasc Res. 2020 Jul 15;116(9):1585-1599. doi: 10.1093/cvr/cvaa124. Cardiovasc Res. 2020. PMID: 32365196 Review.
-
A role for inositol triphosphate in intracellular Ca2+ mobilization and granule secretion in platelets.J Biol Chem. 1985 Dec 5;260(28):15172-9. J Biol Chem. 1985. PMID: 3934155
-
Mediation of cardiac ischemia by thromboxanes released from human platelets.Surgery. 1982 Aug;92(2):292-8. Surgery. 1982. PMID: 7048597
-
Prevention of ventricular fibrillation, acute myocardial infarction (myocardial necrosis), heart failure, and mortality by bretylium: is ischemic heart disease primarily adrenergic cardiovascular disease?Am J Ther. 2004 Sep-Oct;11(5):366-411. doi: 10.1097/01.mjt.0000126444.24163.81. Am J Ther. 2004. PMID: 15356432 Review.
-
Role of antiarrhythmic therapy in patients at risk for sudden cardiac death: an evidence-based review.Pharmacotherapy. 2001 May;21(5):556-75. doi: 10.1592/phco.21.6.556.34550. Pharmacotherapy. 2001. PMID: 11349745 Review.
Cited by
-
Lung megakaryocytes display distinct transcriptional and phenotypic properties.Blood Adv. 2020 Dec 22;4(24):6204-6217. doi: 10.1182/bloodadvances.2020002843. Blood Adv. 2020. PMID: 33351116 Free PMC article.
-
A panel of blood biomarkers unique to sudden cardiac arrest.Heart Rhythm. 2023 Mar;20(3):414-422. doi: 10.1016/j.hrthm.2022.12.014. Epub 2022 Dec 13. Heart Rhythm. 2023. PMID: 36521734 Free PMC article.
-
Do platelets promote cardiac recovery after myocardial infarction: roles beyond occlusive ischemic damage.Am J Physiol Heart Circ Physiol. 2018 May 1;314(5):H1043-H1048. doi: 10.1152/ajpheart.00134.2018. Epub 2018 Mar 16. Am J Physiol Heart Circ Physiol. 2018. PMID: 29547023 Free PMC article.
-
Clofazimine, but Not Isoniazid or Rifampicin, Augments Platelet Activation in vitro.Front Pharmacol. 2018 Nov 20;9:1335. doi: 10.3389/fphar.2018.01335. eCollection 2018. Front Pharmacol. 2018. PMID: 30515097 Free PMC article.
-
Interactions between Platelets and Tumor Microenvironment Components in Ovarian Cancer and Their Implications for Treatment and Clinical Outcomes.Cancers (Basel). 2023 Feb 17;15(4):1282. doi: 10.3390/cancers15041282. Cancers (Basel). 2023. PMID: 36831623 Free PMC article. Review.
References
-
- Ahn Y. K., Cho J. G., Park W. S., Kim N. H., Kim J. W., Kim S. H., Cho J. H., Park J. H., Jeong M. H., Park J. C., Kang J. C. (1999). The effects of antiplatelet agents in the prevention of ventricular tachyarrhythmias during acute myocardial ischemia in rats. Jpn. Heart J. 40, 79–8610.1536/jhj.40.79 - DOI - PubMed
-
- Akar J. G., Akar F. G. (2007). Regulation of ion channels and arrhythmias in the ischemic heart. J. Electrocardiol. 40, S37–S41 - PubMed
-
- Alloatti G., Montrucchio G., Camussi G. (1990). Prostacyclin inhibits the platelet-dependent effects of platelet-activating factor in the rabbit isolated heart. J. Cardiovasc. Pharmacol. 15, 745–751 - PubMed
-
- Ashton J. H., Benedict C. R., Fitzgerald C., Raheja S., Taylor A., Campbell W. B., Buja L. M., Willerson J. T. (1986). Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries. Circulation 73, 572–578 - PubMed
LinkOut - more resources
Full Text Sources